Blood Plasma Derivatives Market Size, Share, and Trends 2024 to 2034

Blood Plasma Derivatives Market Size and Forecast 2024 to 2034

The global blood plasma derivatives market size is estimated at USD 49.39 billion in 2024 and is anticipated to reach around USD 113.75 billion by 2034, expanding at a CAGR of 8.70% from 2024 to 2034.

Blood Plasma Derivatives Market Key Takeaways

• By type, the Immunoglobulin was highest contributor in 2023 and accounted for 48% of revenue share.
• By application, other applications accounted for 39% market share in 2023.
• By end user, the hospital segment accounted for 63% market share in 2023.
• The North America region has captured the highest revenue share of over 47% in 2023.

U.S. Blood Plasma Derivatives Market Size and Growth 2024 to 2034

The U.S. blood plasma derivatives market size is evaluated at USD 16.25 billion in 2024 and is predicted to be worth around USD 38.09 billion by 2034, rising at a CAGR of 8.87% from 2024 to 2034.

Geographically, North America collected a significant offer in the global market in 2023 and is supposed to keep on ruling during the figure time frame, attributable to increment in the number of endorsements of plasma inferred item, and flood in the number of central participants to fabricate plasma determined item in the area. In any case, Asia-Pacific is supposed to enroll the most noteworthy CAGR of 11.0% from 2024 to 2034, attributable to ascend in the pervasiveness of dangerous illnesses, and a flood in mindfulness about the utilization of plasma inferred items among doctors and customers.

Asia Pacific blood plasma derivatives market is set to pick up speed through 2034 prompted by the higher purchaser family wages and the rising patient mindfulness in the locale. The flood in the number of R&D exercises and the raising government subsidizing will likewise add to the territorial development. Vital coordinated efforts, that incorporate acquisitions, organizations, and consolidations alongside speculations, specialized movements, and novel item dispatches are a portion of the key procedures utilized by significant blood plasma derivatives industry members to fortify their market position.

For example, in January 2019, JRC (The Japanese Red Cross Society) marked an eight-year contract with Abbott to make the organization a select provider of immunoassay serological instrumentation, and tests.

On another occasion, in May 2020, the European Blood Alliance (EBA) combined efforts with the European Commission, comprising DG SANTE, DG CNECT, and DG DIGIT. This association assisted with working as well as dealing with an EU-wide, open-access stage that assembles information on the COVID-19 gaining strength plasma treatment.

Blood Plasma Derivatives Market Growth Factors

The worldwide blood plasma derivatives market is noticing energetic development by expanding instances of hemophilia combined with the upgrade in the wellbeing-related issues because of the evolving way of life. Further, rising medical services consumption and expansion in immunodeficiency sicknesses are assessed to help the development of the market. Furthermore, rising government drives for plasma collection and its effective use and expanded mindfulness among individuals are driving the development of the market.

Factors, for example, rising interest in the innovative work, development of medical services areas, developing pace of geriatric populace, and expanding reception of plasma inferred items are expected to raise the pieces of the pie. The expansion in the number of endorsements for blood plasma derivatives drives the development of the market. Furthermore, a flood in the number of clinical examinations for assessing security and proficiency of a wide scope of restorative medications is expected to contribute to the development of the global market. 

As indicated by the diary of BMC Infectious Disease, in November 2021, it was accounted for that the healing plasma treatment is utilized for the patient contaminated with the COVID-19. The Meta - investigation clinical preliminary is led to breaking down the proficiency and adequacy of recuperating plasma. The outcome shows the decline in the death rate in COVID-19 patients by gaining strength plasma treatment.

Besides, ascend in R&D exercises to foster high-level plasma inferred items is supposed to give gainful open doors to the extension of the worldwide market during the conjecture time frame. In addition, the presence of key assembling organizations to make and disperse plasma items and ascend in consumption of medical care items move the development of the market. Drives have been taken by the government and confidential associations to foster the drug industry and push the development of the market. In any case, the secondary effects caused because of the purpose of blood plasma derivatives, for example, unfavorably susceptible conditions, dazedness, quick pulses, and brevity in breath are supposed to confine the blood plasma derivatives market development during the figure time frame.

As per WHO, out of 250,000 individuals diagnosed to have PID (primary immune deficiencies) in the USA in 2017, roughly 125,000 get month-to-month mixtures of immunoglobulins and it is assessed that more than 300,000 patients overall get month-to-month immunoglobulins implantations for PID. The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the blood plasma derivatives market.

WHO also appraises that the global population over 60 years will almost twofold from 12% to 22% somewhere in the range between 2015 and 2050 and 80% of the aging population will be living in middle-income nations in 2050. The expansion in the maturing population around the world might trigger a spike in infections that require plasma treatment. Accordingly, an ascent in the geriatric populace will assist the development of the market.

Market Scope

 Type Insights

By type, the immunoglobulin portion ruled the blood plasma derivatives market in 2023, some of the elements driving the development of the North American blood plasma derivatives market are the rising utilization of plasma-derived products, the presence of leading driving players, the strategic developments made by the organizations in this region and this pattern is supposed to go on during the gauge time frame, inferable from advancements in R&D exercises in the medical care area and expansion in the predominance of safe lacking issues. Nonetheless, the albumin fragment is supposed to observe impressive development during the conjecture time frame because of expansion in egg whites item use for non-restorative application and ascend in the reception of albumin items.

Application Insights

By application, the other application fragment was the significant benefactor in 2023 and is supposed to keep up with its lead during the conjecture time frame, attributable to increment in the commonness of irresistible infection, and expansion popular for plasma determined items. In any case, the immunodeficiency infections fragment is supposed to observe significant development during the conjecture time frame, inferable from ascending in the predominance of safety issues and development in medical services use.

End-User Insights

Based on the end client, the hospitals' fragment ruled the blood plasma derivatives market in 2023, and this pattern is supposed to go on during the conjecture time frame, attributable to increment in the predominance of the constant and irresistible, for example, immunodeficiency turmoil, hemophilia, and drive taken by the government and confidential association to foster development medical care area. Nonetheless, the center portion is supposed to observe extensive development during the estimated time frame, attributable to an increment in the number of facility areas.

Blood Plasma Derivatives Market Top Companies

• Bayer AG
• Biotest AG
• CSL limited
• Fusion Health Care Pvt. Ltd.
• Grifols, S.A.
• Kedrion Biopharma, Inc.
• LFB S.A.
• Octa Pharma AG
• Sanofi
• Takeda

Key Market Developments

• In August 2020, Kedrion Biopharma (Italy) began the improvement of a plasma-inferred treatment for treating the COVID-19 infection that could make it accessible to patients in just three to a half years.
• Grifols, S.A. (Spain) is gathering blood plasma derivatives for the delivery of hyper-immune globulin with an increased number of antibodies from recuperated COVID-19 patients for the potential treatment of Covid illness.

Segments Covered in the Report

By Type

• Albumin
• Factor VIII
• Factor IX
• Immunoglobulin
• Hyperimmune Globulin
• Others

By Application

• Haemophilia
• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Von Willebrand’s Disease
• Other

By End-User

• Hospitals
• Clinics
• Other End Users

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)